Navigation Links
Your baby's brain on drugs (and alcohol and tobacco)
Date:4/7/2008

Although behavioral studies clearly indicate that exposure to drugs, alcohol and tobacco in utero is bad for a babys developing brain, specific anatomic brain effects have been hard to tease out in humans. Often users dont limit themselves to one substance, and demographic factors like poverty can also influence brain development.

Now, an NIH-funded study using magnetic resonance imaging (MRI) brain scans, led by Childrens Hospital Boston neurologist Michael Rivkin, MD, suggests that prenatal exposure to cocaine, alcohol, marijuana or tobacco (alone or in combination) may have effects on brain structure that persist into early adolescence. The findings, published in the April issue of Pediatrics, are of public health significance, the researchers say, since its estimated that more than 1 million babies born annually in the United States have been exposed to at least one of these agents in utero.

Researchers at Childrens and Boston Medical Center employed volumetric MRI imaging to study the brain structure of 35 young adolescents prenatally exposed to cocaine, marijuana, alcohol or tobacco. The children, who averaged 12 years old at the time of imaging, were part of part of an historic cohort of children assembled by Deborah Frank, MD at Boston Medical Center and followed there since birth. Prenatal exposures were confirmed by a combination of maternal history, urine testing of the mother or urine or meconium (stool) testing of the infants at birth.

We found that reductions in cortical gray matter and total brain volumes were associated with prenatal exposure to cocaine, alcohol or cigarettes, says Rivkin, who is first author on the study. Importantly, although volume reductions were associated with each of these three prenatal exposures, they were not associated with any one of these substances alone after controlling for other exposures.

Notably, the effects were found to be additive the more substances a child was expos
'/>"/>

Contact: James Newton
james.newton@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Invasion of the brain tumors
2. HIV is a double hit to the brain
3. AIDS interferes with stem cells in the brain
4. 60 second test could help early diagnosis of common brain diseases
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Influence of sex and handedness on brain is similar in capuchin monkeys and humans
8. Inside the brain of a crayfish
9. Specific brain protein required for nerve cell connections to form and function
10. Brains timing linked with timescales of the natural visual world
11. Adult brain can change, study confirms
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Your baby's brain on drugs (and alcohol and tobacco)
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... patient,s body, stem cells intended to treat or cure ... they are no longer under the control of the ... solve this problem, according to a perspective article from ... a recent issue of the journal Cell Stem ...
... traffic lights the scourge of Britain,s roads! But now ... misery of motorists caused by the repair, maintenance and ... reveal how new technology will allow workers to virtually ... seminar at The University of Nottingham on June 11th ...
... popular belief, aggressive dogs are NOT trying to assert ... to research published by academics at the University of ... Journal of Veterinary Behavior, Clinical Applications and Research . ... interacting at a Dogs Trust rehoming centre, and reanalysing ...
Cached Biology News:Gene therapy could expand stem cells' promise 2Reducing the roadworks 2Reducing the roadworks 3Using 'dominance' to explain dog behavior is old hat 2
(Date:6/1/2015)... BATON ROUGE, La. , June 1, 2015 /PRNewswire/ ... a Phase II trial of lead candidate EP-100 in ... targeted membrane-disrupting peptide designed to seek and destroy cancer ... their surfaces. LHRH receptors are over-expressed in a wide ... randomized, multi-center Phase II trial of EP-100 ...
(Date:6/1/2015)... -- Shire plc (LSE: SHP, NASDAQ: ... the Jefferies 2015 Global Healthcare Conference in ... 2015. Jeff Poulton , Chief Financial Officer will ... a.m. ET (3:00 p.m. BST). A live ... Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/year-2015.aspx ...
(Date:6/1/2015)... 1, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced positive, new, ... trial of AST-VAC1 in patients with intermediate and ... the Company,s autologous (using cells sourced from the ... the most common form of acute leukemia in ...
(Date:5/31/2015)... , May 31, 2015 Halozyme ... company developing novel oncology and drug-delivery therapies, today ... clinical study of its investigational new drug PEGPH20 ... pancreatic cancer. The encouraging interim data ... Clinical Oncology annual meeting in an oral presentation ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... BEIJING, China, Oct. 2 /PRNewswire-Asia-FirstCall/ -- Yongye International,Inc. (Nasdaq: ... manufacturer,developer and distributor of Shengmingsu brand plant and animal ... announced its 2010-,2012 strategic plan. , ... and thus far in,2009, Yongye expects to achieve at ...
... ... with the addition of Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) ... Situational Leadership V (SLV) series specifically for biotech and specialty pharma companies. The new ...
... LAFAYETTE, Ind. - Researchers have overcome a major obstacle ... to create a new class of electronics that would ... Carbon nanotubes, which were discovered in the early 1990s, ... as well as ultra-thin "nanowires" for electronic circuits. The ...
Cached Biology Technology:Yongye International Announces 2010-2012 Strategic Plan 2Yongye International Announces 2010-2012 Strategic Plan 3Yongye International Announces 2010-2012 Strategic Plan 4Yongye International Announces 2010-2012 Strategic Plan 5Perceptum Group Announces New Situational Leadership V Series 2Better control of carbon nanotube 'growth' promising for future electronics 2Better control of carbon nanotube 'growth' promising for future electronics 3
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
interferon-related developmental regulator 2...
Biology Products: